Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
3 institutional releases
Published in Nature · View the paper (DOI)
A new study published in Nature links casdatifan, an investigational HIF-2a inhibitor, to improved clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) patients. Deep suppression of serum EPO correlated with higher response rates and longer progression-free survival.
Coverage from 3 institutions
- New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan Arcus Biosciences Inc · Jul 1, 2026 · first to report
- Next-generation HIF-2α inhibitor shows promise in kidney cancer translational clinical trial Dana-Farber Cancer Institute · Jul 1, 2026
- Study: Casdatifan demonstrates durable tumor responses in heavily pretreated patients with advanced kidney cancer University of Miami Miller School of Medicine · Jul 27, 2026